Björn Stapela

Responsible for comercial evaluation and input on Pre clinical, Phase I and II CNS compound developments. Member of the BD and L team for in licensing (including due diligence) of new compounds

Co-ordinate Global Strategic Plan ensuring worldwide implementation across major markets. Manage EU launch team activity (submission registration).Support worldwide market penetration efforts. Key success factor assimilation & dissemination, proactively address customer (Product Manager) needs. Lead the marketing team for customer initiatives. Plan prepare and manage International Product Manager meetings. Support US marketing activities with global specific initiated activities.

Develop the Swiss market for the launch of the Novartis Cox 2 Specific Inhibitor. Identify and select K.O.L for support in the market development prior to launch. Establish and initiate local Primary and Secondary Advisory Board. Member of the MPH implementation group, responsible for the execution of the company’s MPH plans

The planning and execution of the launch of VIOXX (Rofecoxib) in South Africa. Best worldwide launch of VIOXX (Post Celebrex) Selected as Merck Marketing Principles champion for MSD (SA). Responsible for communication and implementation of international Merck Marketing Principles at local subsidiary level. Active member of International Marketing Team. Assessment of global marketing strategies.

Launched Zantac 75 (Glaxo’s biggest Selfmedproduct) successfully in South Africa Strategic Planning, formulating marketing plans, forecasting, budgeting and execution of marketing plans

Planning and conducting all cycle meetings, setting of individual targets, monitoring the weekly sales performance, controlling and monitoring of bonus stock, developing and maintaining Key opinion leader relationships.

B COM Marketing, Marketing, Economics, Business Economics